全球PD-1 和PD-L1 抑製劑市場- 市場規模、份額和增長分析：按類型（PD-1 抑製劑、PD-L1 抑製劑）、按應用（癌症、自身免疫性疾病）、按最終用戶（醫院、診所）、行業預測（2023-2030）

Global PD-1 And PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Type(PD-1 inhibitors, and PD-L1 inhibitors), By Application(Cancer, Autoimmune Diseases), By End-User(Hospitals, Clinics) - Industry Forecast 2023-2030

出版日期: 2023年07月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021年全球PD-1和PD-L1抑製劑市場價值將達到303億美元，2022年將達到356億美元。預計該市場在預測期內（2023-2030年）將以17.5%的複合年增長率擴張，並於2030年增長至1293.6億美元。

由於癌症患病率上升和免疫療法的日益採用，全球 PD-1 和 PD-L1 抑製劑市場正在經歷顯著增長。 PD-1和PD-L1抑製劑在調節免疫系統方面發揮著重要作用，使免疫系統能夠識別並有效攻擊癌細胞。這些抑製劑在各種癌症類型中顯示出有希望的結果，導致它們在腫瘤學中廣泛使用。製藥行業的主要進入者正在投資研發以推出創新的 PD-1 和 PD-L1 抑製劑，進一步推動市場擴張。

推動 PD-1 和 PD-L1 抑製劑市場的主要因素之一是癌症患病率的上升。全球各種類型癌症的患病率不斷增加，增加了對有效和有針對性的免疫治療的需求。 PD-1 和 PD-L1 抑製劑已成為抗擊癌症的有前途的治療選擇，因為它們在幫助免疫系統識別癌細胞並更有效地對抗它們方面發揮著重要作用。Masu。因此，癌症發病率的增加刺激了 PD-1 和 PD-L1 抑製劑在腫瘤學領域的採用，推動了市場增長。

PD-1和PD-L1抑製劑市場面臨的製約因素之一是藥品成本上漲。先進的免疫療法、PD-1 和 PD-L1 抑製劑的開發和製造成本可能很高，導致患者的治療成本高昂。這一成本因素限制了一些患者獲得挽救生命的治療，並可能影響癌症治療中 PD-1 和 PD-L1 抑製劑的總體吸收。製藥公司和醫療保健提供者必須應對這一挑戰，以使這些創新療法更廣泛地可用且負擔得起。

本報告研究了全球 PD-1 和 PD-L1 抑製劑市場，提供了市場概述以及按類型、應用、最終用戶、地區和進入市場的公司劃分的趨勢。我們提供概況等。

內容

執行摘要

母公司市場分析

市場概覽
市場規模
市場動態
驅動程序
機會
制約因素
任務
主要市場洞察
技術分析
價格分析
供應鏈分析
價值鏈分析
市場生態系統
知識產權分析
貿易分析
初創企業分析
原材料分析
創新矩陣
管道產品分析
宏觀經濟指標
熱門投資分析
關鍵成功因素
爭用程度
市場動態和前景
市場動態
驅動程序
機會
制約因素
任務
監管狀況
波特分析

全球 PD-1 和 PD-L1 抑製劑市場（按類型）

市場概覽
PD-1抑製劑
PD-L1抑製劑

全球 PD-1 和 PD-L1 抑製劑市場（按應用）

市場概覽
癌症
自身免疫性疾病
其他

全球 PD-1 和 PD-L1 抑製劑市場（按最終用戶）

市場概覽
醫院
診所
其他

全球 PD-1 和 PD-L1 抑製劑市場（按地區）

市場概覽
北美
歐洲
亞太地區
拉丁美洲
中東和非洲

競爭格局

主要公司簡介
AstraZeneca
BeiGene
BioInvent
Bristol-Myers Squibb
CStone Pharmaceuticals
Eli Lilly and Company
F. Hoffmann-La Roche AG
Incyte Corporation
Innovent Biologics
Jiangsu Hengrui Medicine
Kyowa Kirin
Merck & Co.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals
Sanofi S.A
Shanghai Junshi Biosciences
Sorrento Therapeutics
Takeda Pharmaceutical Company Limited
TG Therapeutics

簡介目錄

Product Code: SQMIG35I2102

Market Insights

Global PD-1 And PD-L1 Inhibitors Market size was valued at USD 30.3 billion in 2021 and is poised to grow from USD 35.6 billion in 2022 to USD 129.36 billion by 2030, growing at a CAGR of 17.5% in the forecast period (2023-2030).

The global PD-1 and PD-L1 inhibitors market is witnessing significant growth due to the rising prevalence of cancer and the increasing adoption of immunotherapy treatments. PD-1 and PD-L1 inhibitors play a crucial role in the modulation of the immune system, enabling it to recognize and attack cancer cells effectively. These inhibitors have shown promising results in various cancer types, leading to their widespread use in oncology. Key players in the pharmaceutical industry are investing in research and development to introduce innovative PD-1 and PD-L1 inhibitors, further propelling market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of PD-1 And PD-L1 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global PD-1 And PD-L1 Inhibitors Market Segmental Analysis

PD-1 And PD-L1 Inhibitors Market is segmented by type, application, and end-user. Based on type, the PD-1 And PD-L1 Inhibitors Market can be segmented into PD-1 inhibitors, and PD-L1 inhibitors. Based on application, the PD-1 And PD-L1 Inhibitors Market can be segmented into cancer, autoimmune diseases, and others. Based on end-users, the PD-1 And PD-L1 Inhibitors Market is segmented into hospitals, clinics, and others. Based on region, the PD-1 And PD-L1 Inhibitors Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver

One of the key drivers propelling the PD-1 and PD-L1 inhibitors market is the increasing incidence of cancer. The growing prevalence of various types of cancer worldwide has led to a greater demand for effective and targeted immunotherapy treatments. PD-1 and PD-L1 inhibitors have emerged as promising therapeutic options in the fight against cancer, as they play a crucial role in enabling the immune system to recognize and combat cancer cells more effectively. As a result, the rising occurrence of cancer has fueled the adoption of PD-1 and PD-L1 inhibitors in oncology, driving market growth.

Restraints

One of the restraints faced by the PD-1 and PD-L1 inhibitors market is the escalating cost of these drugs. As advanced immunotherapies, PD-1 and PD-L1 inhibitors can be expensive to develop and produce, resulting in higher treatment costs for patients. This cost factor may limit access to these life-saving treatments for some individuals, affecting the overall adoption of PD-1 and PD-L1 inhibitors in cancer therapy. Pharmaceutical companies and healthcare providers need to address this challenge to ensure wider accessibility and affordability of these innovative therapies.

Market Trends

In the global PD-1/PD-L1 inhibitors market is the increasing emphasis on combination therapies. Evidence suggests that combining PD-1/PD-L1 inhibitors with other drugs, such as chemotherapy or other immunotherapies, can enhance their efficacy and mitigate the risk of resistance. Major market players are making substantial investments in the development of such combination therapies, with numerous new regimens currently undergoing clinical trials. This trend is anticipated to persist in the future as researchers and healthcare professionals strive to enhance patient outcomes and overcome the limitations of using PD-1/PD-L1 inhibitors as standalone treatments.